백신 시장 : 적응 질환별, 기술별, 유형별, 투여 경로별, 최종사용자별, 지역별 - 예측(-2030년)

The vaccines market is expected to reach 63.66 billion USD in 2030, up from 50.46 billion USD in 2025, growing at a CAGR of 4.8% during the forecast period.

Factors such as the high incidence of contagious diseases, innovation in vaccine technology, government support and substantial funding for vaccine development, increasing vaccination initiatives, and a strong focus on investing in and launching innovative products are driving this growth vaccines.

In 2024, by disease indication, the pneumococcal segment accounted for the largest share of the vaccines market.

Based on disease indication, the vaccines market is segmented into combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, pneumococcal disease, influenza, varicella, hepatitis, DTP, polio, and other disease indications. In 2022, the pneumococcal segment held the largest share of the vaccines market. This is due to several key factors: a rising incidence of pneumococcal infections worldwide; increased government funding for vaccination programs; and heightened public awareness of the serious health risks associated with pneumococcal-related complications such as pneumonia, meningitis, and bloodstream infections. Additionally, ongoing innovation and the development of next-generation pneumococcal vaccines, such as the recently approved 20-valent and 21-valent conjugate vaccines, are expanding immunization options, further boosting market growth and public health benefits outcomes.

In 2024, by type, the multivalent vaccines segment accounted for the largest share of the vaccines market.

The vaccines market is divided into monovalent vaccines and multivalent vaccines, based on type. In 2024, the multivalent vaccines segment held the largest portion of the Vaccines market. This dominance comes from the ability of multivalent vaccines to provide protection against multiple diseases with a single dose-simplifying immunization by reducing the number of injections needed, which increases patient compliance and decreases logistical challenges. Additionally, the growing prevalence of diseases that require broad-spectrum immunity, such as respiratory infections and certain cancers, has increased demand for these vaccines. Further supporting this trend are technological advances and increased investment in efficient manufacturing of multivalent vaccines, enabling larger and faster production. Governments and healthcare providers in regions with limited healthcare access particularly favor them because simplified vaccination schedules improve coverage and boost public health outcomes.

In 2024, the Asia Pacific was the fastest growing region in the Vaccines market.

The vaccines market region is divided into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa. The Asia Pacific region is expected to grow at a significant CAGR during the forecast period. This increase is driven by greater public health awareness, expanding national immunization programs, and increased government investment in healthcare infrastructure. Supporting these efforts are public-private partnerships, international collaborations aimed at improving vaccine equity, and technological advancements that enable advanced vaccine development and more affordable production. Additionally, the region's large and growing populations, especially in countries such as China and India, present a substantial target market for both established and new vaccines. These factors highlight the Asia Pacific's leadership in the vaccine industry market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
• By Designation: C-level Executives - 55%, Directors- 20%, and Others- 25%
• By Region: North America -35%, Europe - 25%, Asia Pacific -20%, Latin America -10%, the Middle East & Africa- 10%

GSK plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec (India), Biological E. Limited (India), Bharat Biotech (India), Novavax (US), Inovio Pharmaceuticals (US), Sinovac (China), Incepta Pharmaceuticals (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), Bio Farma (Indonesia), FSUE NPO Microgen (Russia), Zhi fei Biological (China), Indian Immunologicals Ltd (India) are some of the key companies offering Vaccines.

Research Coverage

This research report categorizes the Vaccines market by technology (conjugate vaccine, recombinant vaccine, inactivated & subunit vaccine, live attenuated vaccine, toxoid vaccine, viral vector vaccine, mRNA vaccine, and other vaccines), type (monovalent vaccines, multivalent vaccines), indication (pneumococcal disease, influenza, combination vaccine, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, RSA, other disease indications), route of administration (intramuscular & subcutaneous, oral, other routes), end user (pediatric vaccines, adult vaccines), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the vaccines market. A comprehensive analysis of key industry players has been conducted to offer insights into their business overview, product portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments related to the vaccines market. Competitive analysis of top players and upcoming startups within the vaccines market ecosystem is included in this report. The report also details primary factors like drivers, restraints, challenges, and opportunities shaping the market growth, along with an in-depth review of key industry players' solutions, products, recent product launches, mergers, acquisitions, and emerging market trends ecosystem.

Key Benefits of Buying the Report

This report offers a comprehensive overview of the Vaccines market. It aims to assess the size and future growth opportunities of the market across various segments, such as technology, type, indication, route of administration, end user, and region. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies.

The report provides insights into the following pointers:

Analysis of key drivers (strong emphasis on investment and launch of novel vaccines, rising prevalence of infectious disease, expanding immunization programs, advancements in vaccine technology and robust government support & funding for the development of vaccines), restraints (High development cost, patent expiry ), opportunities (Increased focus on therapeutic vaccines, robust & strong pipeline) and challenges (Stringent regulatory processes, vaccine supply shortage, frequent product recall)

• Product Development/Innovation: Detailed insights on newly launched Products, and technological assessment of the Vaccines market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the Vaccines market across varied regions.
• Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the Vaccines market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as GSK plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec (India), Biological E. Limited (India), Bharat Biotech (India), Novavax (US), Inovio Pharmaceuticals (US), Sinovac (China), Incepta Pharmaceuticals (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), Bio Farma (Indonesia), FSUE NPO Microgen (Russia), Zhi fei Biological (China), Indian Immunologicals Ltd (India), among others, in the vaccines market. The report also helps stakeholders understand the trends of the vaccines market and provides information on key market drivers, restraints, challenges, and opportunities. A detailed analysis of the key industry players has been conducted to offer insights into their key strategies, product launches and approvals, pipeline developments, acquisitions, partnerships, collaborations, recent activities, investments, and funding activities, brand and product comparisons, vendor evaluations, and financial metrics of the vaccines sector market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key sources of secondary data
    • 2.1.1.2 Key objectives of secondary research
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Breakdown of primaries
    • 2.1.2.2 Key objectives of primary research
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 GLOBAL MARKET SIZE ESTIMATION, 2024
    • 2.2.1.1 Company revenue analysis (bottom-up approach)
    • 2.2.1.2 MarketsandMarkets repository analysis
    • 2.2.1.3 Secondary analysis
    • 2.2.1.4 Bottom-up approach (disease indication-based analysis)
    • 2.2.1.5 Primary research
      • 2.2.1.5.1 Insights from primary sources
  • 2.2.2 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

• 3.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS IN VACCINES MARKET
• 3.3 DISRUPTIVE TRENDS SHAPING VACCINES MARKET
• 3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS

4 PREMIUM INSIGHTS

• 4.1 GLOBAL VACCINES MARKET SNAPSHOT
• 4.2 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE AND COUNTRY, 2024
• 4.3 VACCINES MARKET (EXCLUDING COVID-19 VACCINES): GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 UNMET NEEDS & WHITE SPACES
• 4.5 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES
• 4.6 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS
• 4.7 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.8 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Focus on vaccine development and launches
    • 5.2.1.2 Rising prevalence of infectious diseases
    • 5.2.1.3 Increasing immunization programs
    • 5.2.1.4 Advancements in vaccine technology
    • 5.2.1.5 Government support and funding for vaccine development
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of vaccine development
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Rising focus on therapeutic vaccines
    • 5.2.3.2 Extensive R&D for vaccines and increased investments in clinical trials
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Stringent regulatory processes
    • 5.2.4.2 Product recalls

6 INDUSTRY TRENDS

• 6.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 6.2 PRICING ANALYSIS
  • 6.2.1 AVERAGE SELLING PRICE TREND OF VACCINES, BY KEY PLAYER, 2023-2025
  • 6.2.2 AVERAGE SELLING PRICE TREND OF VACCINES, BY DISEASE INDICATION, 2023-2025
  • 6.2.3 AVERAGE SELLING PRICE TREND OF VACCINES, BY REGION, 2021-2023
• 6.3 TECHNOLOGY ANALYSIS
  • 6.3.1 KEY TECHNOLOGIES
    • 6.3.1.1 Recombinant technology
    • 6.3.1.2 Conjugation technology
    • 6.3.1.3 Viral vector technology
  • 6.3.2 COMPLEMENTARY TECHNOLOGIES
    • 6.3.2.1 Encapsulation & delivery technology
    • 6.3.2.2 Automation & control
    • 6.3.2.3 AI & machine learning for vaccine design
  • 6.3.3 ADJACENT TECHNOLOGIES
    • 6.3.3.1 Single-use technology
    • 6.3.3.2 Cell line development
• 6.4 VALUE CHAIN ANALYSIS
• 6.5 PIPELINE ANALYSIS
  • 6.5.1 VACCINES MARKET: CLINICAL TRIALS, BY PHASE
  • 6.5.2 VACCINES MARKET: CLINICAL TRIALS, BY DISEASE INDICATION
  • 6.5.3 VACCINES MARKET: PHASE 2/3 CLINICAL TRIALS, BY COMPANY
• 6.6 ECOSYSTEM ANALYSIS
  • 6.6.1 VACCINES MARKET: ROLE IN ECOSYSTEM
• 6.7 REGULATORY ANALYSIS
  • 6.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 6.7.2 REGULATORY FRAMEWORK
    • 6.7.2.1 North America
    • 6.7.2.2 Europe
    • 6.7.2.3 Asia Pacific
    • 6.7.2.4 Latin America
    • 6.7.2.5 Middle East & Africa
  • 6.7.3 REGULATORY CHALLENGES IN VACCINES MARKET
• 6.8 TRADE ANALYSIS
  • 6.8.1 IMPORT DATA (HS CODE 300220)
  • 6.8.2 EXPORT DATA (HS CODE 300220)
• 6.9 PORTER'S FIVE FORCES ANALYSIS
  • 6.9.1 THREAT OF NEW ENTRANTS
  • 6.9.2 THREAT OF SUBSTITUTES
  • 6.9.3 BARGAINING POWER OF SUPPLIERS
  • 6.9.4 BARGAINING POWER OF BUYERS
  • 6.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 6.10 PATENT ANALYSIS
  • 6.10.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR VACCINE PATENTS, 2014-2024
• 6.11 KEY CONFERENCES & EVENTS, 2025-2026
• 6.12 KEY STAKEHOLDERS & BUYING CRITERIA
  • 6.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 6.12.2 KEY BUYING CRITERIA
• 6.13 INVESTMENT & FUNDING SCENARIO
• 6.14 IMPACT OF AI/GENERATIVE AI ON VACCINES MARKET
  • 6.14.1 INTRODUCTION
  • 6.14.2 MARKET POTENTIAL OF AI IN VACCINES MARKET
  • 6.14.3 AI USE CASES
  • 6.14.4 KEY COMPANIES IMPLEMENTING AI
  • 6.14.5 FUTURE OF GENERATIVE AI IN VACCINES ECOSYSTEM
• 6.15 IMPACT OF 2025 US TARIFFS ON VACCINES MARKET
  • 6.15.1 INTRODUCTION
  • 6.15.2 KEY TARIFF RATES
  • 6.15.3 PRICE IMPACT ANALYSIS
  • 6.15.4 IMPACT ON COUNTRY/REGION
    • 6.15.4.1 US
    • 6.15.4.2 Europe
    • 6.15.4.3 Asia Pacific
  • 6.15.5 IMPACT ON END-USE INDUSTRIES
    • 6.15.5.1 Public health & government bodies
    • 6.15.5.2 Healthcare providers & institutions
• 6.16 VACCINE PROCUREMENT DATA
  • 6.16.1 NUMBER OF VACCINES DELIVERED BY UNICEF, 2023-2025
  • 6.16.2 WHO: VACCINE PURCHASE DATABASE, 2021-2023
• 6.17 VACCINE MANUFACTURING PROCESS
  • 6.17.1 OVERVIEW
    • 6.17.1.1 R&D and process development
    • 6.17.1.2 Upstream production (antigen generation)
    • 6.17.1.3 Downstream processing
    • 6.17.1.4 Formulation & fill-finish
    • 6.17.1.5 Quality control & regulatory release
    • 6.17.1.6 Packaging, cold chain, and distribution
  • 6.17.2 MANUFACTURING MODELS & CAPACITY DYNAMICS

7 VACCINES MARKET, BY DISEASE INDICATION

• 7.1 INTRODUCTION
• 7.2 PNEUMOCOCCAL DISEASE
  • 7.2.1 INCREASING INCIDENCE OF PNEUMONIA IN CHILDREN TO DRIVE MARKET
• 7.3 INFLUENZA
  • 7.3.1 RISING NEED FOR IMMUNIZATION AGAINST VIRAL INFECTIONS TO DRIVE MARKET
• 7.4 COMBINATION VACCINES
  • 7.4.1 GROWING DEMAND FOR ALL-IN-ONE VACCINES TO DRIVE MARKET GROWTH
• 7.5 HPV
  • 7.5.1 RISING FOCUS ON CERVICAL CANCER PREVENTION TO DRIVE HPV VACCINE UPTAKE
• 7.6 MENINGOCOCCAL DISEASE
  • 7.6.1 INCREASING INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS TO SUPPORT MARKET GROWTH
• 7.7 HERPES ZOSTER
  • 7.7.1 RISING AGING POPULATION TO DRIVE DEMAND FOR HERPES ZOSTER VACCINES
• 7.8 ROTAVIRUS
  • 7.8.1 RISING INFANT IMMUNIZATION PROGRAMS TO DRIVE ROTAVIRUS VACCINE MARKET GROWTH
• 7.9 MMR
  • 7.9.1 RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA TO BOOST DEMAND
• 7.10 VARICELLA
  • 7.10.1 INCREASING PROMOTION OF IMMUNIZATION PROGRAMS TO SUPPORT MARKET GROWTH
• 7.11 HEPATITIS
  • 7.11.1 LOW SOCIO-ECONOMIC STANDARDS OF LIVING AND HIGH CONTAMINATION IN DRINKING WATER TO DRIVE MARKET
• 7.12 DTP
  • 7.12.1 STRONG INTEGRATION INTO NATIONAL IMMUNIZATION PROGRAMS TO SUSTAIN DTP VACCINE DEMAND
• 7.13 POLIO
  • 7.13.1 INCREASING GOVERNMENT INITIATIVES AND IMMUNIZATION PROGRAMS TO DRIVE MARKET
• 7.14 RSV
  • 7.14.1 STRONG PRODUCT PIPELINE AND NEW PRODUCT LAUNCHES TO PROPEL MARKET GROWTH
• 7.15 COVID-19
  • 7.15.1 DECLINING DEMAND DUE TO HIGH POPULATION COVERAGE AND REDUCED SEVERITY OF VARIANTS TO SLOW DOWN MARKET GROWTH
• 7.16 OTHER DISEASE INDICATIONS

8 VACCINES MARKET, BY TECHNOLOGY

• 8.1 INTRODUCTION
• 8.2 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY
  • 8.2.1 CONJUGATE VACCINES
    • 8.2.1.1 Increasing public-private partnerships to drive market growth
  • 8.2.2 RECOMBINANT VACCINES
    • 8.2.2.1 Low post-vaccination reactions and reduced need for booster doses to drive market
  • 8.2.3 INACTIVATED & SUBUNIT VACCINES
    • 8.2.3.1 Ease of storage and transportation to support growth
  • 8.2.4 LIVE ATTENUATED VACCINES
    • 8.2.4.1 High cost of storage and limited financial resources of distributors to restrain market
  • 8.2.5 TOXOID VACCINES
    • 8.2.5.1 Rising prevalence of bacterial infections among infants and children to drive market
  • 8.2.6 OTHER VACCINES
• 8.3 COVID-19 VACCINES MARKET, BY TECHNOLOGY
  • 8.3.1 MRNA VACCINES
    • 8.3.1.1 Increasing focus on mRNA vaccine development to drive market
  • 8.3.2 VIRAL VECTOR VACCINES
    • 8.3.2.1 Rising investment in vaccine development to drive market
  • 8.3.3 OTHER COVID-19 VACCINES

9 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE

• 9.1 INTRODUCTION
• 9.2 MULTIVALENT VACCINES
  • 9.2.1 INCREASED NEED FOR IMMUNIZATION AND COST-EFFECTIVENESS TO DRIVE MARKET
• 9.3 MONOVALENT VACCINES
  • 9.3.1 RISING R&D INVESTMENTS AND PREVALENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH

10 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION

• 10.1 INTRODUCTION
• 10.2 INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION
  • 10.2.1 EASE OF ABSORPTION AND BETTER IMMUNE RESPONSE TO DRIVE ADOPTION
• 10.3 ORAL ADMINISTRATION
  • 10.3.1 REDUCED RISK OF BLOOD-TRANSMITTED INFECTIONS TO DRIVE ADOPTION
• 10.4 OTHER ROUTES OF ADMINISTRATION

11 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER

• 11.1 INTRODUCTION
• 11.2 ADULT VACCINES
  • 11.2.1 ADULT VACCINES TO COMMAND LARGER MARKET SHARE DURING FORECAST PERIOD
• 11.3 PEDIATRIC VACCINES
  • 11.3.1 SUPPORT FROM GOVERNMENT AND NON-GOVERNMENT BODIES TO DRIVE MARKET

12 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 12.2.2 US
    • 12.2.2.1 US to dominate North American market during forecast period
  • 12.2.3 CANADA
    • 12.2.3.1 High incidence of infectious diseases to drive market growth
• 12.3 EUROPE
  • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 12.3.2 GERMANY
    • 12.3.2.1 Significant R&D investments and growing biotechnology industry to drive market
  • 12.3.3 UK
    • 12.3.3.1 Launch of new products and increased funding by government and non-government organizations to drive market
  • 12.3.4 FRANCE
    • 12.3.4.1 Favorable government initiatives for mass immunization to drive market
  • 12.3.5 ITALY
    • 12.3.5.1 Higher investments by companies for increased production capacities to drive market
  • 12.3.6 SPAIN
    • 12.3.6.1 Rising investments in vaccine development by private organizations to drive market
  • 12.3.7 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 12.4.2 CHINA
    • 12.4.2.1 China to hold largest share of APAC vaccines market
  • 12.4.3 JAPAN
    • 12.4.3.1 Favorable government initiatives to support market growth
  • 12.4.4 INDIA
    • 12.4.4.1 Increasing government initiatives and development of new and improved vaccines to drive market
  • 12.4.5 SOUTH KOREA
    • 12.4.5.1 Strong government strategies for improved vaccine hubs to drive market
  • 12.4.6 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 12.5.2 BRAZIL
    • 12.5.2.1 Rising focus on immunization programs to drive market
  • 12.5.3 MEXICO
    • 12.5.3.1 Trained workforce and ethnically varied population base for clinical trials to propel market growth
  • 12.5.4 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST
  • 12.6.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
  • 12.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
• 12.7 AFRICA
  • 12.7.1 AVAILABILITY OF FUNDS AND GRANTS FROM DEVELOPED ECONOMIES TO DRIVE MARKET
  • 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN VACCINES MARKET
• 13.3 REVENUE ANALYSIS, 2020-2024
• 13.4 MARKET SHARE ANALYSIS, 2024
• 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 13.5.1 STARS
  • 13.5.2 EMERGING LEADERS
  • 13.5.3 PERVASIVE PLAYERS
  • 13.5.4 PARTICIPANTS
  • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 13.5.5.1 Company footprint
    • 13.5.5.2 Region footprint
    • 13.5.5.3 Technology footprint
    • 13.5.5.4 Type footprint
    • 13.5.5.5 Route of administration footprint
• 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 13.6.1 PROGRESSIVE COMPANIES
  • 13.6.2 RESPONSIVE COMPANIES
  • 13.6.3 DYNAMIC COMPANIES
  • 13.6.4 STARTING BLOCKS
  • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
    • 13.6.5.1 Detailed list of key startups/SMEs
    • 13.6.5.2 Competitive benchmarking of key startups/SMEs
• 13.7 COMPANY VALUATION & FINANCIAL METRICS
  • 13.7.1 FINANCIAL METRICS
  • 13.7.2 COMPANY VALUATION
• 13.8 BRAND/PRODUCT COMPARISON
  • 13.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 PRODUCT LAUNCHES & APPROVALS
  • 13.9.2 DEALS
  • 13.9.3 EXPANSIONS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 GSK PLC
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Product launches & approvals
      • 14.1.1.3.2 Deals
      • 14.1.1.3.3 Expansions
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Key strengths
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses & competitive threats
  • 14.1.2 MERCK & CO., INC.
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Product approvals
      • 14.1.2.3.2 Deals
      • 14.1.2.3.3 Expansions
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses & competitive threats
  • 14.1.3 PFIZER INC.
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Product approvals
      • 14.1.3.3.2 Deals
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses & competitive threats
  • 14.1.4 SANOFI
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product approvals
      • 14.1.4.3.2 Deals
      • 14.1.4.3.3 Expansions
      • 14.1.4.3.4 Other developments
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Key strengths
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses & competitive threats
  • 14.1.5 CSL
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Product approvals
      • 14.1.5.3.2 Deals
      • 14.1.5.3.3 Expansions
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Key strengths
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses & competitive threats
  • 14.1.6 EMERGENT
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product approvals
      • 14.1.6.3.2 Other developments
  • 14.1.7 JOHNSON & JOHNSON SERVICES, INC.
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Deals
  • 14.1.8 ASTRAZENECA
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Deals
      • 14.1.8.3.2 Expansions
      • 14.1.8.3.3 Other developments
  • 14.1.9 SERUM INSTITUTE OF INDIA PVT., LTD.
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Product launches & approvals
      • 14.1.9.3.2 Deals
      • 14.1.9.3.3 Expansions
  • 14.1.10 BAVARIAN NORDIC
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Product approvals
      • 14.1.10.3.2 Deals
      • 14.1.10.3.3 Other developments
  • 14.1.11 MITSUBISHI TANABE PHARMA CORPORATION
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Product launches & approvals
      • 14.1.11.3.2 Deals
  • 14.1.12 DAIICHI SANKYO COMPANY, LIMITED
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Deals
  • 14.1.13 PANACEA BIOTEC
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products offered
    • 14.1.13.3 Recent developments
      • 14.1.13.3.1 Deals
  • 14.1.14 BIOLOGICAL E LIMITED
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products offered
    • 14.1.14.3 Recent developments
      • 14.1.14.3.1 Product approvals
      • 14.1.14.3.2 Deals
      • 14.1.14.3.3 Other developments
  • 14.1.15 BHARAT BIOTECH
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products offered
    • 14.1.15.3 Recent developments
      • 14.1.15.3.1 Product launches & approvals
      • 14.1.15.3.2 Deals
  • 14.1.16 NOVAVAX
    • 14.1.16.1 Business overview
    • 14.1.16.2 Products offered
    • 14.1.16.3 Recent developments
      • 14.1.16.3.1 Product approvals
  • 14.1.17 INOVIO PHARMACEUTICALS
    • 14.1.17.1 Business overview
    • 14.1.17.2 Products offered
    • 14.1.17.3 Recent developments
      • 14.1.17.3.1 Other developments
• 14.2 OTHER PLAYERS
  • 14.2.1 SINOVAC
  • 14.2.2 INCEPTA PHARMACEUTICALS LTD.
  • 14.2.3 VALNEVA SE
  • 14.2.4 VBI VACCINE INC.
  • 14.2.5 BIO FARMA
  • 14.2.6 MICROGEN
  • 14.2.7 ZHI FEI BIOLOGICAL
  • 14.2.8 INDIAN IMMUNOLOGICALS LIMITED

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS